The Efficacy, Safety and Tolerability of Canakinumab in the Treatment of Familial Mediterranean Fever: A Systematic Review of the Literature

• Main Authors: Kacar M (Author), Savic S (Author), van der Hilst JCH (Author)
• Format: Book
• Published: Dove Medical Press, 2020-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 1178-7031
• Keywords: familial mediterranean fever; canakinumab; anti-il1 therapy; Pathology; RB1-214; Therapeutics. Pharmacology; RM1-950
• Source: Journal of Inflammation Research, Vol Volume 13, Pp 141-149 (2020)

Mark Kacar,1 Sinisa Savic,1 Jeroen CH van der Hilst2,3 1Department of Clinical Immunology and Allergy, St James´s University Hospital, Leeds, UK; 2Department of Infectious Diseases and Immunity, Jessa Hospital, Hasselt, Belgium; 3BIOMED Research Institute, University of Hasselt, Hasselt, BelgiumCorrespondence: Jeroen CH van der HilstDepartment of Infectious Diseases and Immunity, Jessa Hospital, Stadsomvaart 11, Hasselt 3500, BelgiumTel [phone]Email [e-mail]: Familial Mediterranean Fever (FMF) is the most prevalent genetic autoinflammatory disorder. In most patients, treatment with colchicine can prevent attacks of fever and inflammation. However, 5%– 10% of patients are resistant to colchicine treatment, while a similar percentage cannot tolerate colchicine in doses needed to prevent attacks. For these patients, Canakinumab, a full human antibody against IL-1β, has been approved recently by the FDA and EMA. In this article, we present a systematic review of the long-term efficacy, safety, and tolerability of Canakinumab in FMF patients who cannot tolerate colchicine or who are resistant to colchicine treatment.Keywords: familial mediterranean fever, Canakinumab, anti-IL1 therapy